Proven bioequivalence of blood exposure between vinorelbine 80 mg/m(2) oral and 30 mg/m(2) IV doses in cancer patients.

Authors
Publication date
Publisher
'American Society of Clinical Oncology (ASCO)'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Newcastle University E-Prints

    redirect
    oaioai:eprints.ncl.ac.uk:97533
    Last time updated on 30/05/2021